World News
-
Philips expands connected patient monitoring ecosystem with six technology partnerships
The partnerships will enable healthcare providers to integrate wearable and out-of-hospital monitoring technologies into the Philips ecosystem.
-
Sobi strikes US$580M lacutamab deal with Innate Pharma for CTCL
The study is designed to provide confirmatory evidence for lacutamab in two CTCL subtypes, Sézary syndrome and mycosis fungoides, potentially supporting full regulatory approval.
-
Innovent Biologics to commercialise Daiichi Sankyo’s Vanflyta in China
Vanflyta received approval in China in June 2026 for use in adults with newly diagnosed FLT3-ITD-positive AML, as determined by an appropriate validated diagnostic test.
-
Tarsus Pharmaceuticals to acquire Alkeus in US$800M deal to expand ophthalmology pipeline
The centerpiece of the deal is gildeuretinol, formerly known as ALK-001, a once-daily oral therapy under development for Stargardt disease, a rare inherited retinal disorder.
-
Takeda secures FDA approval for oral orexin agonist Orzeyful in US market
The approval expands Orzeyful’s commercial reach following its authorization in China in July 2026, marking another milestone in Takeda’s global launch strategy.
-
Mediar Therapeutics collaborates with Ono Pharma on fibro-inflammatory antibody therapies
Under the agreement, Ono will work with Mediar to identify potential treatments using the biotechnology company’s fibrosis-focused discovery platform and expertise in myofibroblast biology and fibrosis-related pathways.
-
Dr. Reddy’s ends distribution agreement with Novartis India due to ownership change
Under the four-year agreement, Novartis India had granted Dr Reddy’s an exclusive and non-transferable right to promote, distribute and sell certain products in the Indian market.
-
US researchers use generative AI to design functional synthetic viruses in scientific breakthrough
The team chemically synthesised nearly 300 of the AI-generated genomes and tested them in laboratory conditions, with sixteen of the resulting viruses proving viable.
-
Evotec inks AI drug discovery deal with Odyssey Therapeutics for inflammatory diseases
The companies will combine Evotec’s screening technologies, compound libraries and AI-enabled discovery platform with Odyssey’s expertise in the biology of autoimmune and inflammatory diseases.
-
Eli Lilly discontinues Gaucher type 1 gene therapy trial from Prevail buyout
Lilly disclosed the decision as part of its second-quarter results, removing a phase 1/2 study of LY3884961 in Gaucher disease type 1 (GD1) from its pipeline.